|
[Symposium 01] Airway Disease 1 - Controversies and Perspectives in Airway Diseases |
15:10-16:30 |
||
|---|---|---|---|
| Chair | |||
| 10:30-11:00 | SY 1-1 |
Controversies and Opportunities in Severe Asthma
|
|
| 11:00-11:30 | SY 1-2 |
Current Controversies and Future Perspectives in COPD
|
|
| 11:30-12:00 | SY 1-3 |
The Importance of Real-life Research in Respiratory Medicine
|
|
|
[Luncheon Symposium 01] Airway Disease
|
11:00-12:00 |
||
| Chair | |||
| 12:00-12:30 | LS 1 |
Which Types of Asthma Patients Would Benefit from Omalizumab?
|
|
|
[Symposium 02] Airway Disease 2 - Current and Future of Using Biomarkers in the Management of Airway Diseases |
15:10-16:00 |
||
| Chair | |||
| 13:30-14:00 | SY 2-1 |
Blood and Sputum Eosinophil as a Biomarker of COPD
|
|
| 14:00-14:30 | SY 2-2 |
Biomarkers and Biologics for Severe Asthma
|
|
| 14:30-15:00 | SY 2-3 |
Multi-Omics Based Precision Medicine in Asthma
|
|
|
[Satellite Symposium 1] Airway Disease
|
09:00-10:30 |
||
| Chair | |||
| 17:15-17:45 | SS 1-1 |
Why Wouldn’t We Intervene Earlier in Patients at Risk of Exacerbation?
|
|
| 17:45-18:15 | SS 1-2 |
Should You Initiate Treatment with One or Two Bronchodilators?
|
|
|
[Satellite Symposium 3] Interstitial Lung Disease / Airway Disease
|
09:00-10:30 |
||
| Chair | |||
| 17:15-17:45 | SS 3-1 |
Exploring Optimal Treatment Options for Progressive Fibrosing ILDs : How to Treat?
|
|
| 17:45-18:15 | SS 3-2 |
What Do COPD Real World Studies Tell Us about LAMA/LABA Initiation in Maintenance Therapy?
|
|